Goldman Sachs Maintains Neutral on Intellia Therapeutics, Lowers Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on Intellia Therapeutics and lowers the price target from $31 to $20.

October 25, 2024 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Goldman Sachs has maintained a Neutral rating on Intellia Therapeutics but has lowered the price target from $31 to $20, indicating a less optimistic outlook.
The lowering of the price target by Goldman Sachs suggests a less favorable view on Intellia's near-term prospects, which could lead to a negative impact on the stock price. The Neutral rating indicates no strong buy or sell recommendation, but the significant reduction in the price target is likely to weigh on investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100